Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Randomized, Non-comparative Study Evaluating the Impact of Short Message Service (SMS) on Compliance With Surveillance of Patients With Germ-cell Tumors. (TEXTIS Study)

NCT03868176 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT03868176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03868176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Randomized, Non-comparative Study Evaluating the Impact of Short Message Service (SMS) on Compliance With Surveillance of Patients With Germ-cell Tumors. (TEXTIS Study)
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Observational
Overall status
Unknown status
Start date
February 28, 2019
Completion date
August 31, 2021
Enrollment
235 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

compliance, patient, follow-up, germ cell tumor, text messaging